Acute respiratory failure is a significant complication of severe pneumococcal pneumonia. In a mouse model, we observed early-onset lung microvascular leakage after pulmonary infection with Streptococcus pneumoniae, and we hypothesized that the important virulence factor pneumolysin may be the direct causative agent.
Controlled, in vivo, ex vivo, and in vitro laboratory study.
Female mice, 8–12 wks old.
Ventilated and blood-free perfused murine lungs were challenged with recombinant pneumolysin via the airways as well as via the vascular bed. In addition, we analyzed the impact of pneumolysin on electrical cell impedance and hydraulic conductivity of human umbilical vein endothelial cell (HUVEC) and alveolar epithelial cell (A549) monolayers.
Aerosolized pneumolysin dose-dependently increased capillary permeability with formation of severe lung edema but did not affect pulmonary vascular resistance. Intravascular pneumolysin caused an impressive dose-dependent increase in pulmonary vascular resistance and in lung microvascular permeability. By immunohistochemistry, pneumolysin was detected mainly in endothelial cells of pulmonary arterial vessels, which concomitantly displayed strong vasoconstriction. Moreover, pneumolysin increased permeability of HUVEC and A549 monolayers. Interestingly, immunofluorescence of endothelial cell monolayers exposed to pneumolysin showed gap formation and moderate stress fiber generation.
Pneumolysin may play a central role for early-onset acute lung injury due to severe pneumococcal pneumonia by causing impairment of pulmonary microvascular barrier function and severe pulmonary hypertension.
From Charité-Universitätsmedizin Berlin, Department of Internal Medicine/Infectious Diseases and Pulmonary Medicine, Berlin, Germany (MW, BG, ACH, BS, SH, KB, SR, NS, HS); Division of Infection and Immunity, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, United Kingdom (TJM); and Area de Immunología, Facultad de Medicina, Universidad de Oviedo, Oviedo, Spain (JRT).
Supported, in part, by grants from Charité (HS, MW) and from BMBF (SR, SH, BS, NS) (CAPNETZ—competence network community acquired pneumonia C4 and C15).
The authors do not have any financial interests to disclose.